FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME

FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME

Anticoagulation treatment is a vital component of acute coronary syndrome treatment. Selection of the most efficient and safe drug for the acute coronary syndrome patients without ST elevation (NSTEACS) depends on the strategy of treatment and is in fact a difficult task. Fondaparinux (Arixtra) is a...

Full description

Bibliographic Details
Main Authors: G. V. Mardaryan, S. A. Abugov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2015-09-01
Series:Российский кардиологический журнал
Subjects:
acute coronary syndrome
nsteacs
anticoagulation
pci
fondaparinux
enoxaparin
myocardial infarction
bleeding
Online Access:https://russjcardiol.elpub.ru/jour/article/view/253
Description
Summary:Anticoagulation treatment is a vital component of acute coronary syndrome treatment. Selection of the most efficient and safe drug for the acute coronary syndrome patients without ST elevation (NSTEACS) depends on the strategy of treatment and is in fact a difficult task. Fondaparinux (Arixtra) is a synthetic Xa factor clotting inhibitor, has showed its benefits in clinical studies, according to which it is included into clinical guidelines. Current review focuses on the main results and conclusions of the studies, and the place for fondaparinux in clinical practice is described
ISSN:1560-4071
2618-7620

Similar Items